|Generic name||Calaspargase pegol-mknl|
|Pronunciation||kal-AS-par-jase PEG-ol mknl|
|Brand name(s), other common name(s)||AsparlasTM|
|Drug type||Asparagine specific enzyme|
|How the drug is given||Intravenous|
Indications and Usage
Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Side effects needing medical attention
The most common adverse reactions were elevated transaminase (a liver enzyme), bilirubin increased, pancreatitis and abnormal clotting.